As only approximately 25 % of the bulk tumor cells are DR5+ at the time of analysis, we questioned how continued treatment with drozitumab leads to tumor growth inhibition and regression seen in Fig. 1. The gene discussed is TNFRSF10B; the disease is neoplasm.